"Immunoglobulin G" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
| Descriptor ID |
D007074
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.393 D12.776.124.790.651.114.619.393 D12.776.377.715.548.114.619.393
|
| Concept/Terms |
IgG(T)- IgG(T)
- Immunoglobulin GT
- GT, Immunoglobulin
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin G".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin G".
This graph shows the total number of publications written about "Immunoglobulin G" by people in this website by year, and whether "Immunoglobulin G" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 3 | 3 | 6 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 7 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 4 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 6 | 5 | 11 |
| 2022 | 2 | 12 | 14 |
| 2023 | 1 | 10 | 11 |
| 2024 | 2 | 6 | 8 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin G" by people in Profiles.
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
-
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS. 2025 Mar 15; 39(4):448-456.
-
Relationships Among COVID-19-Related Service Uptake, HIV Status, Drug Use, and COVID-19 Antibody Status Among HIV Testing Intervention Participants in KwaZulu-Natal, South Africa. Int J Environ Res Public Health. 2024 Oct 25; 21(11).
-
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
-
Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura. Vox Sang. 2024 Dec; 119(12):1285-1294.
-
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27; 16(9).
-
Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
-
Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2330138.
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
-
Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response. Clin Immunol. 2024 02; 259:109877.